Edison Pharmaceuticals has entered into a strategic alliance with Dainippon Sumitomo Pharma Co., Ltd. (DSP) for the development of drugs targeting cellular energy metabolism, in a deal with a potential value of $4.3 billion. The R&D program will focus on the characterization of the redox control energy system, which is critical to the generation and regulation of cellular energy metabolism. The companies maintain that the cellular redox “network” is an untapped reservoir of new d...